Corcept Therapeutics Clinical Trials
Sponsors / Corcept Therapeutics
The ClinicalTrials.gov registry records 74 trials led by Corcept Therapeutics. Across the portfolio, 5 are in recruitment, 5 are active non-recruiting, and 56 have reached completion. 7 trials have been terminated or withdrawn. The most common reasons cited for termination include slow or insufficient recruitment, efficacy or futility findings. Across the portfolio, planned enrollment totals 7,882 participants. Data on this page mirrors the ClinicalTrials.gov registry as of the most recent refresh.
74
Total Trials
5
Recruiting
5
Other Active
56
Completed
7
Terminated / Withdrawn
7,882
Total Enrollment
Termination reasons: Other57% · Recruitment14% · Efficacy14% · Safety14%
Recent Terminations
- Metastatic Pancreatic Ductal Adenocarcinoma"The independent data monitoring committee found no safety issues, however the observed response rate did not meet the predefined threshold for continuing the study. The study was terminated by the Sponsor."
- Central Adrenal Insufficiency"low recruitment"
- Nonalcoholic Steatohepatitis (NASH)"Suspended by sponsor, pending investigation of abnormal laboratory values in patients with NASH"
- NCT03379363 Stopped Feb 2018Cushing Syndrome"Insufficient number of patients"
- Psychosis"DRC recommended stopping study as it had missed its primary endpoint"
- Alzheimer's Disease
- Cushing's Syndrome
Active Trials (5 total)
- NCT07259317
- NCT06108219
- NCT03604198
- NCT06906341
- Prostate Cancer PHASE1NCT03674814
- NCT05407324
- Neoplasms PHASE1/PHASE2NCT07276373
- NCT06947304
- Healthy PHASE1NCT07240116
- Fallopian Tube Neoplasms PHASE3NCT05257408